jain.com

CoreWeave all-stock acquisition of Core Scientific

Company: Core Scientific

This claim was marked delayed on September 29, 2026. Recorded automatically from the cited source when it was published, then queued for evidence review.

How this was decided: Automated extraction from the cited source. The claim is preserved below exactly as it was originally published, so the record shows what was asserted as well as what became of it.

Subject kind
acquisition
Statement date
2025-10-13
Promised by
2025-12-31
Promised amount
0.1235
Current status
delayed

The claim, verbatim

Core Scientific has a definitive agreement for CoreWeave to acquire it in an all-stock deal, with Core Scientific stockholders receiving 0.1235 newly issued CoreWeave Class A shares per share. The transaction is expected to close in Q4 2025.

Source (primary)

core-scientific 8-K exhibit (ef20056907_ex99-1.htm) (SEC EDGAR (8-K Ex), press_release)
View cached copy (2026-09-28)Live source ↗

Quote: “Core Scientific stockholders to receive 0.1235 newly-issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock held ... Expected to close in Q4 2025”

How we checked this

This claim has not yet been checked assertion-by-assertion against its source. It carries a cited source and quote, but the deeper check has not run. When it does, the result appears here whatever it says.

Additional evidence

confirms core-scientific 8-K exhibit (ef20056907_ex99-1.htm)

Quote: “Core Scientific stockholders to receive 0.1235 newly-issued shares of CoreWeave Class A common stock for each share of Core Scientific common stock held ... Expected to close in Q4 2025”

View cached copy (2026-09-28)Live source ↗

Record of changes

September 28, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
September 29, 2026 — delayed
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.